Incidence of inherited metabolic disorders in southern Israel: A comparison between consanguinity and non-consanguinity communities

CURRENT STATUS: UNDER REVIEW

Guy Hazan
Soroka Medical Center

Eliyahu Hershkovitz
Soroka Medical Center

O Staretz-Chacham
Soroka University Medical Center

staretz@bgu.ac.il Corresponding Author
ORCiD: https://orcid.org/0000-0001-6975-4909

DOI:
10.21203/rs.3.rs-21563/v1

SUBJECT AREAS
Internal Medicine

KEYWORDS
Inherited Metabolic Diseases, Consanguinity, Jewish, Bedouin- Muslim, Prevalence
Abstract

Background - Inherited metabolic disorders (IMDs) are group of rare monogenic diseases, usually derived from reduced or absent activity in a single metabolic pathway. Most of the IMDs are inherited in an autosomal recessive manner. The incidence of IMDs varies from country to country and within different ethnic groups, but data is still scarce. Consanguinity rate among populations is highly contributor factor for IMDs incidence. There are no reports comparing the incidence of IMD in consanguineous and non-consanguineous populations from the same geographic region with the same diagnostic capabilities. Our study objective is to compare the incidence of IMDs between the relatively low consanguineous Jewish population and the consanguineous Bedouin population, both living in the southern of Israel.

Results - During 1990-2017 there were 393,772 live births in the Negev district, of Southern of Israel. Among them 187,049 were of Jewish origin while 206,723 were of Bedouin-Muslim origin. A total of 223 children were diagnosed in this study period with IMDs. Among those 223 children with IMD, 33 were of Jewish origin while the other 190 children were of Bedouin-Muslim origin. The overall incidence for IMDs of the overall Negev population was 56.6/100,000 live birth. The incidence for IMD's among the Bedouin population was significantly higher than among Jewish population.

Conclusions - IMDs are extremely more common in the consanguineous Bedouin compared with the relatively non-consanguineous Jewish population of Southern Israel. Health policy makers should consider these data and prepare educational and genetic counselling problems accordingly.

Background

Inherited metabolic disorders (IMDs) comprise a heterogeneous group of over 500 rare monogenic diseases, mostly derived from reduced or absent activity in a single metabolic pathway\textsuperscript{1,2}. Approximately 80\% of the IMD are inherited in an autosomal recessive manner\textsuperscript{3}. The clinical outcome of IMDs are often severe, however, disease progression and deterioration might be related to delayed timing of the proper diagnosis \textsuperscript{4,5}. There might be an overlap of clinical presentation between different diseases, hence diagnoses of IMD can be challenging.

Reported incidence of IMDs in the literature varies from country to country and even within different
regions in the same country. Although the incidence of each disorder is rare, their cumulative incidence is substantial: 20-40 per 10,000 live birth is often quoted\textsuperscript{5,6}. Despite numerous reports of cumulative incidence of IMD in different countries such as 15.7/100,000 live birth in Australia; 27/100,000 in Italy; 1:2500 in Canada; whilst in West Midlands region in United Kingdom it reaches up to 1:784\textsuperscript{7-10}, there is still lack of data, globally and regionally, about the actual incidence of IMD, this might lead to difficulty in planning and providing appropriate clinical service for the patients. This is becoming more relevant nowadays due to emerging new technologies for diagnosis, screening and treatment\textsuperscript{11-18}.

As described previously, the inheritance pattern of most IMDs is by Autosomal Recessive manner. Hence, in countries and regions with high consanguinity rates, the incidence of IMDs and other rare disorders is increased\textsuperscript{19}. The inbreeding coefficient factors range from 0.00004–0.00008 in Canada, while in Saudi Arabia, where the consanguinity is as high as 40\% among first cousins and up to 60\% in intermarriage between relatives, the inbreeding factor is 0.024\textsuperscript{20-22}. Hence, the incidence of IMDs in Saudi Arabia is reported as 150/100,000 live birth\textsuperscript{23}. However, this incidence can be influenced by a high index of suspicion for IMD in Saudi Arabia. There are no reports comparing the incidence of IMD in consanguineous and non-consanguineous populations from the same geographic region with the same diagnostic capabilities.

Southern Israel is a heterogeneously populated area, inhabited by two major populations – Jewish and Bedouin (Muslim). The Jewish population’s lifestyle is similar to developed countries and the consanguinity rate in this population is relatively low. Whereas, the consanguinity rate in the Bedouin population is relatively high, similar to tribes in Saudi Arabia\textsuperscript{24} and also the tendency to have more children per family. Approximately 45\% of marriages in the Bedouin population in Israel are consanguineous, most of them are first cousin origin\textsuperscript{25}.

Our study aimed to calculate the incidences of various IMDs in southern Israel with comparison of the incidence between the relatively low consanguineous Jewish population and the consanguineous
Bedouin population.

Results

Over 27 years of study period there were 393,772 live births in the Negev district of Southern Israel. Among them 187,049 were of Jewish origin while 206,723 were of Bedouin-Muslim origin. A total of 223 children were diagnosed in this study period with IMDs. All of those children were diagnosed in Soroka University Medical Center (SUMC) by clinical suspicion and/or laboratory testing in hospital or by the Israeli newborn screening program. Among those 223 children with IMD, 33 were of Jewish origin while the other 190 children were of Bedouin-Muslim origin. The overall incidence for IMDs of the Negev population was 56.6/100,000 live birth. The incidence for IMD's among the Bedouin population was significantly higher than among Jewish population (101.6/100,000 Vs 16/100,000, respectively, P value < 0.001), (Table 1).

| Disease category         | Overall incidence/100,000 live births | Incidence among Bedouin-Muslim/100,000 live births | Incidence among Jews/100,000 live births | P value |
|-------------------------|--------------------------------------|--------------------------------------------------|-----------------------------------------|---------|
| Overall                 | 56.6                                 | 101.6                                            | 16                                      | < 0.001 |
| Aminoaciduria           | 8.6                                  | 18.2                                             | 0                                       | < 0.001 |
| Peroxisomal diseases    | 5.3                                  | 9.1                                              | 1.9                                     | < 0.001 |
| Sphingolipidosis        | 4.8                                  | 9.1                                              | 1                                       | < 0.001 |
| Organic Aciduria        | 2                                    | 4.3                                              | 0                                       | 0.003   |
| Fatty Acid Oxidation Diseases | 4.8                               | 7                                                | 2.9                                     | 0.02    |
| Mucopolysaccharosis     | 6.9                                  | 12.8                                             | 1.5                                     | < 0.001 |
| Glycogen Storage diseases* | 11.2                              | 15                                               | 7.7                                     | 0.03    |
| Pompe disease (type 2 Glycogens storage disease) | 2.3                              | 4.8                                              | 0                                       | 0.003   |
| Mitochondrial diseases  | 10.7                                 | 21.4                                             | 1                                       | < 0.001 |

Birth incidence for all IMD's categories was significantly higher among the Bedouin-Muslim population in comparison with the Jewish population, as presented in Table 1. The incidence of Peroxisomal diseases for Bedouin-Muslims per 100,000 live births was 9.1 while for Jewish it was 1.9. Similar differences were demonstrated for Sphingolipidosis (9.1/100,000 for Muslims-Bedouin Vs 1/100,000 for Jewish), Fatty Acid Oxidation Diseases (7/100,000 Vs. 2.9/100,000), Mucopolysaccharidosis (12.8/100,000 Vs 1.5/100,000) and Glycogen Storage Diseases (15/100,000 Vs 7.7/100,000). For
Aminoaciduria’s, Organic acidurias and Pompe disease there were no affected Jewish children while the incidence of Bedouin-Muslims with disease was 18.2/100,000, 4.3/100,000 and 4.8/100,000, respectively.

Table 2 presents the births incidences for each IMD. For most of the diseases’ subtypes the incidence among the Bedouin-Muslim population was higher compared to the Jewish population. The only disease with statistically significant higher incidence among the Jewish population was Glycogen Storage disease type 1A with an incidence of 2.9/100,000 live births among Jewish patients Vs. no affected patients among the Bedouin-Muslims population. For the following diseases the incidence among the Bedouin-Muslims population was statistically significance higher than for the Jewish population: Maple Syrup Urine Disease (10.2/100,000 Vs. 0/100,000, respectively), Non-Ketotic Hyperglycinemia (8/100,000 Vs. 0/100,000, respectively), Zellweger disease (8.2/100,000 Vs. 0.5/100,000, respectively), Niemen-Pick C type 1 (9.1/100,000 Vs. 1/100,000, respectively), Glutaric Aciduria type 1 (4.3/100,000 Vs. 0/100,000, respectively), Very Long Chain Acyl-CoA Dehydrogenase deficiency (4.3/100,000 Vs. 0.5/100,000, respectively), Mucopolysaccharidosis type 3 (3.7/100,000 Vs. 0.5/100,000, respectively) and type 4 (5.9/100,000 Vs. 0/100,000, respectively), Glycogen Storage disease type 1B (8/100,000 Vs. 0.5/100,000, respectively), type 3 (3.7/100,000 Vs. 0/100,000, respectively) and type 6 (4.8/100,000 Vs. 0/100,000, respectively), Pompe disease (4.8/100,000 Vs. 0/100,000, respectively), Complex 1 deficiency (5.9/100,000 Vs. 0/100,000, respectively), Complex 3 deficiency (7/100,000 Vs. 0/100,000, respectively) and Complex 5 deficiency (3.7/100,000 Vs. 0/100,000, respectively).

Table 2
- Incidence of each inherited metabolic disease among Jews Vs. Bedouin-Muslim population, in southern of Israel, between the years 1990–2017

| Disease category | Overall incidence/100,000 live births | Incidence among Bedouin-Muslim/100,000 live births | Incidence among Jews/100,000 live births | P value |
|------------------|--------------------------------------|---------------------------------------------|---------------------------------------|---------|
| Aminoacidopathy: |                                      |                                             |                                       |         |
| Maple Syrup Urine Disease (MSUD) | 4.8 | 10.2 | 0 | < 0.001 |
| Non-Ketotic Hyperglycinemia | 3.8 | 8 | 0 | < 0.001 |
| Peroxisomal diseases: |                                      |                                             |                                       |         |
| X-linked | 0.8 | 0 | 1.6 | 0.1 |
| Condition                                      | Value 1 | Value 2 | Value 3 | Value 4 |
|------------------------------------------------|---------|---------|---------|---------|
| Adrenoleukodystrophy                          | 4.6     | 8.2     | 0.5     | < 0.001 |
| Zellweger disease                             | 4.8     | 9.1     | 1       | < 0.001 |
| Sphingolipidosis:                              |         |         |         |         |
| Niemen Pick C type 1                          | 149     | 253     | 358     | 0.1     |
| **Organic Aciduria:                           | 2       | 4.3     | 0       | 0.003   |
| Glutaric Aciduria type 1                      | 2       | 4.3     | 0       | 0.003   |
| Fatty Acid Oxidation Diseases:                |         |         |         |         |
| Multiple Acyl-coA Dehydrogenase deficiency    | 0.5     | 1       | 0       | 0.1     |
| Medium Chain Acyl-CoA Dehydrogenase deficiency| 1       | 0.5     | 1.5     | 0.4     |
| Very Long Chain Acyl-CoA Dehydrogenase deficiency | 2.3  | 4.3     | 0.5     | 0.1     |
| Very Long Chain Acyl-CoA Dehydrogenase deficiency | 0.3  | 0.5     | 0       | 0.3     |
| Carnitine Palmitoyltransferase 1A             | 0.3     | 0.5     | 0       | 0.3     |
| Carnitine Palmitoyltransferase 2              | 0.5     | 0       | 1       | 0.2     |
| Long Chain 3-hydroxy-CoA Dehydrogenase deficiency | 0.5  | 0.3     | 0       | 0.3     |
| **Mucopolysaccharidosis:                      |         |         |         |         |
| Mucopolysaccharosis type 1                    | 1       | 1.1     | 1       | 0.9     |
| Mucopolysaccharosis type 3                    | 2       | 3.7     | 0.5     | 0.02    |
| Mucopolysaccharosis type 3                    | 2.8     | 5.9     | 0       | < 0.001 |
| Unclassified Mucopolysaccharosis              | 0.8     | 1.1     | 0.5     | 0.6     |
| Glycogen Storage diseases*:                   |         |         |         |         |
| Glycogen Storage disease type 0               | 0.3     | 0       | 0.5     | 0.3     |
| Glycogen Storage disease type 1               | 1.5     | 0       | 2.9     | 0.02    |
| Glycogen Storage disease type 1B              | 4.1     | 8       | 0.5     | < 0.001 |
| Glycogen Storage disease type 3               | 1.8     | 0       | 3.7     | < 0.001 |
| Glycogen Storage disease type 6               | 2.3     | 4.8     | 0       | < 0.001 |
| Glycogen Storage disease type 9               | 0.3     | 0.5     | 0       | 0.3     |
| Glycogen Storage disease type 11              | 0.3     | 0.5     | 0       | 0.3     |
| Unclassified Glycogen Storage disease         | 0.8     | 1.1     | 0.5     | 0.6     |
| **Pompe disease (type 2 Glycogens storage disease)** | 2.3  | 4.8     | 0       | 0.003   |
| Mitochondrial diseases:                       |         |         |         |         |
| Complex 1 deficiency                          | 2.8     | 5.9     | 0       | < 0.001 |
| Complex 3 deficiency                          | 3.3     | 7       | 0       | < 0.001 |
| Complex 5 deficiency                          | 1.8     | 3.7     | 0       | 0.005   |
| **Pyruvate Dehydrogenase Deficiency type 1A** | 0.3     | 0       | 0.5     | 0.3     |
The incidences of other IMD that were included in this study were not statistically different between the 2 populations.

Discussion
In this study we show that in an extremely consanguineous population the incidence of IMD is significantly higher than that of a relatively non consanguineous population. This finding is expected since 80% of IMD are inherited in an autosomal recessive pattern. Yet, these data are important. IMD can be life threatening and the therapies for such disease can be extremely expensive. Health policy makers should be aware that these devastating diseases are relatively common and not rare as expected, in extremely consanguineous populations. In the Bedouin populations IMD occur in at least 1/1000 live births. Prevention of IMD is possible after genetic diagnosis and genetic counselling to at risk families and this should be encouraged. Although consanguinity is considered to be rare in developed countries, in many populations in different geographic areas, consanguinity is common, suggesting that IMD as well as other genetic diseases are extremely more common in these populations.

Although the incidence of genetic diseases reflects the prevalence of genetic mutations in the population, it is noteworthy that the Bedouin population tends to have larger families. This can also affect the total incidence of IMD shown in this study. Since our aim was to compare the "real life" incidences of IMD in these populations, we did not use statistical methods to account for the possibility of a mother having more than one affected child. As a result, we did not calculate the prevalence of genetic mutations in the populations studied.
Additionally, there is a higher rate of absent prenatal care and lower rate of pregnancy termination, even with diagnosed devastating diseases, in the Bedouin population\textsuperscript{28,29}. In order to prevent these cases, prenatal and premarital genetic consultation should be encouraged by all the caregivers of affected families, including raising the possibilities of Pre-implantation Genetic Diagnosis (PGD). Since the Bedouin population has a high rate of consanguinity, there is also an increased number of founder effect, and the combination of large inbreeding families with high consanguinity rate is expected to result in a higher number of, although rare, recurring mutations in this population. The only disease with a significantly higher prevalence in the Jewish population is glycogen storage disease type 3 and all patients originate from Northern Africa were in the past there was high consanguinity rate among the Jewish population (Table 2), additionally glycogen storage disease type 1A is more common, though not significantly, in the Jewish population of Ashkenazi origin, again due to past increased consanguinity.

Patients’ recollection for this study had been performed in the pre and post newborn screening era. It should be mentioned that since May 2009 Israel established universal Newborn Screening program\textsuperscript{30}. Since then, there might be increasing diagnostic rate for the relevant diseases (Medium chain Acyl-Coa Dehydrogenase deficiency, Very Long Chain Acyl-CoA Dehydrogenase deficiency and Maple Syrup Urine Disease). Zlotogora et al reported of a significant increase in the number of genes with variants causing autosomal recessive diseases among Israeli Arabs in the last several years\textsuperscript{31}. It was presumed that it is mostly the result of the availability of better diagnostic possibilities for molecular diagnosis in genes already well known. Therefore, we should take into consideration that prior to this screening the diagnosed patients were those with relatively more severe clinical course. The above mentioned led us to the conclusion that prior to the universal newborn screening there was underestimation of the "true" incidence of IMDs. Also, we assume that even in now there is still an underestimation of the "true" incidence, given the fact that many of these diseases are still not diagnosed (for example, in cases of early mortality or in cases of subtle disease that has not included in the newborn screening yet).

Conclusion
IMDs are significantly more common in the consanguineous Bedouin compared with the relatively non-consanguineous Jewish population of Southern Israel. In the Bedouin population, IMD should not be considered as "rare" diseases since at least 1/1000 live birth has an IMD. Health policy should take into account these data.

Methods

Settings

The Negev district of Southern Israel was inhabited by 643,000 individuals in 2012 according to the Israeli Central Bureau of Statistics; of these, 64% were Jews. Of the whole Negev population, 12% were children <4 years old (77,000 children); among them 48% were Jewish children. Between 1990-2017 there were 187,049 Bedouin live birth and 206,723 Jewish live birth; overall of 393,772 live birth. Those numbers served as denominator for incidence calculations. Bedouin and Jewish children in the southern of Israel have access to the same medical services. Medical insurance in Israel is free and universal therefore there are no financial barriers in the availability of hospital services. The Soroka University Medical Center (SUMC) is the only hospital that serves the entire region. All births and evaluation of suspected IMDs are referred to SUMC. This exclusivity enables us to calculate incidence of IMDs according to ethnicity.

Study design

This is a retrospective study conducted at SUMC from 1990 to 2017. The following inherited metabolic diseases were evaluated:

Aminoacidopathies – Maple Syrup Urine Disease (MSUD), Non-Ketotic Hyperglycinemia;
Peroxisomal diseases – X-linked Adrenoleukodystrophy (ALD), Zellweger disease;
Sphingolipidosis – Niemann–Pick disease type 1;
Organic acidemia – Glutaric Aciduria; Propionic academia; Isovaleric acidemia
Fatty acid oxidation disease – Multiple Acyl-Coa Dehydrogenase deficiency (MADD), Medium chain Acyl-Coa Dehydrogenase deficiency (MCAD), Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD), Carnitine Palmitoyl-transferase 1A (CPT 1A), Carnitine Palmitoyl-transferase 2 (CPT 2), Long chain 3-hydroxyl-CoA Dehydrogenase deficiency (LCHAD);
Lysosomal storage diseases- Mucopolysaccharidosis types I, III,IVa, VI
Glycogen Storage diseases – type 0, 1A, 1B, 2, 3, 6, 9, 11.
 Mitochondrial diseases - Complex 1 deficiency, Complex 3 deficiency, Complex 5 deficiency, Pyruvate dehydrogenase deficiency types 1A and Dihydrolipoamide dehydrogenase deficiency, Kearns Sayre
syndrome, Mitochondrial Neuro-Gastrointestinal encephalopathy disease (MNGIE), Trans-Membrane protein 70 deficiency (TMEM 70), Mitochondrial DNA depletion. Details were extracted from the computerized data of metabolic unit in SUMC.

Statistical analysis

Incidence rates were calculated per specific disease in each ethnic origin separately and compared using Chi square test of Fisher exact test as appropriate. Comparison between the ethnic origin and incidences were performed. 95% confidence interval was calculated; \( P \) value of <.05 was considered significant. This study was approved by SUMC ethical committee.

Declarations

Ethics approval - this study was approved by the ethic committee of Soroka University Medical Center.

Consent for publication - not applicable.

Availability of data - the datasets used and/or analyzed during the current study are available from the corresponding author for reasonable request.

Conflict of interest - The authors declare that they have no conflict of interest.

Funding - There was no funding.

Acknowledgment - not applicable.

Authors' contributions -

GH was responsible for conduct, epidemiological analysis and reporting of the study.

EH was responsible for conduct and reporting of the study.

OSC was responsible for planning, conduct and reporting of the study.

All authors read and approved the final manuscript.

References

1. Scrivner CR, Beaudet AL, Sly WS et al. The metabolic and molecular bases of inherited diseases, Vol1. New York: McGraw-Hill, 2001:53-118.

2. Tebani A, Abily-Donval L, Afonso C, Marret S, Bekri S. Clinical Metabolomics: The New Metabolic Window for Inborn Errors of Metabolism Investigations in the Post-Genomic
3. Afzal RM, Lund AM, Skovby F. The impact of consanguinity on the frequency of inborn errors of metabolism. Mol Genet Metab Rep. 2018 Jan 11;15:6-10. doi: 10.1016/j.ymgmr.2017.11.004. eCollection 2018 Jun. PMID:29387562

4. Jimenez-Sanchez G, Childs B, Valle D. Human disease genes. Nature 2001; 409:853-5.

5. Martins AM. Inborn errors of metabolism: a clinical overview. Sao Paulo Med J.1999 Nov 4;117(6):251-65.

6. Seymour CA, Thomason MJ, Chalmers RA, Addison GM, Bain MD, Cockburn F, Littlejohns P, Lord J, Wilcox AH. Newborn screening for inborn errors of metabolism: a systematic review. Health Technol Assess. 1997;1(11):i-iv, 1-95. Review. PMID:9483156.

7. Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med. 2003;348:2304-12. 5.

8. Dionisi-Vici C, Rizzo C, Burlina AB, Caruso U, Sabetta G, Uziel G, et al. Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey. J Pediatr. 2002;140:321-7.

9. Sanderson S, Green A, Preece MA, Burton H. The incidence of inherited metabolic disorders in the West Midlands, UK. Arch Dis Child. 2006;91:896-9.

10. Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics. 2000;105:e10

11. Wilcken B, Wiley V, Hammond J, et al. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. New Engl J Med 2003;348:2304-12. 9

12. Venditti LN, Venditti CP, Berry GT, et al. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a
costeffectiveness analysis. Pediatrics 2003;112:1005-15.

13. Pandor A, Eastham J, Beverley C, et al. Clinical effectiveness and costeffectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess 2004;8:1-121.

14. Muller E, Kolker S. Reduction of lysine intake while avoiding malnutrition— major goals and major problems in dietary treatment of glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2004;27:903-10.

15. Miebach E. Enzyme replacement therapy in mucopolysaccharidosis type I. Acta Paediatr Suppl 2005;94:58-60.

16. Mignani R, Cagnoli L. Enzyme replacement therapy in Fabry’s disorder: recent advances and clinical applications. J Nephrol 2004;17:354-63.

17. Eto Y, Shen JS, Meng XL, et al. Treatment of lysosomal storage disorders: cell therapy and gene therapy. J Inherit Metab Dis 2004;27:411-5.

18. Sauer M, Grewal S, Peters C. Hematopoietic stem cell transplantation for mucopolysaccharidoses and leukodystrophies. Klin Padiatr 2004;216:163-8.

19. Broides A, Nahum A, Mandola AB, Rozner L, Pinsk V, Ling G, Yerushalmi B, Levy J, Givon-Lavi N. Incidence of typically Severe Primary Immunodeficiency Diseases in Consanguineous and Non-consanguineous Populations. J Clin Immunol. 2017 Apr;37(3):295-300. doi: 10.1007/s10875-017-0378-6. Epub 2017 Mar 16. PMID:28299599.

20. El-Hazmi MA, Warsy A. Genetic disorders among Arab populations. Saudi Med J. 1996;17:108-23.

21. El-Hazmi MA, al-Swailem AR, Warsy AS, alSwailem AM, Sulaimani R, al-Meshari AA. Consanguinity among the Saudi Arabian population. J Med Genet. 1995;32:623-6.

22. Al-Gazali L, Hamamy H, Al-Arrayad S. Genetic disorders in the Arab world. BMJ.
23. Moammar H, Cheriyan G, Mathew R, Al-Sanna N.
Incidence and patterns of inborn errors of metabolism in the Eastern Province of
Saudi Arabia, 1983-2008. Ann Saudi Med. 2010 Jul-Aug; 30(4): 271-7. doi:
10.4103/0256-4947.65254.

24. Al-Saud B, Al-Mousa H, Al Gazlan S, Al-Ghonaium A, Arnaout R, Al-Seraihy A.
Primary immunodeficiency diseases in Saudi Arabia: a tertiary care hospital experience over
a period of three years (2010-2013). J Clin Immunol. 2015; 35: 651-60.

25. Na’amnih W, Romano-Zelekha O, Kabaha A, Rubin LP, Bilenko N, Jaber L, et al.
Prevalence of consanguineous marriages and associated factors among Israeli
Bedouins. J Community Genet. 2014; 5: 395-8.

26. Central Bureau of Statistics Israel. statistical abstract of Israel.
http://www.cbs.gov.il/shnaton64/st02_19x.pdf. Accessed June 2018.

27. Bradford L. Therrell Jr., Michele A. Lloyd-Puryear, Kathryn M. Camp, Marie Y. Mann.
Inborn errors of metabolism identified via newborn screening: ten-year incidence
data and costs of nutritional interventions for research agenda planning. Molecular
Genetics and Metabolism. Volume 113, issues 1-2, September-October 2014, Pages
14-26.

28. Abu-Ghanem S, Sheiner E, Sherf M, Wiznitzer A, Sergienko R, Shoham-Vardi I.
Lack of prenatal care in a traditional community: trends and perinatal outcomes. Arch
Gynecol Obstet. 2012 May; 285(5): 1237-42. doi: 10.1007/s00404-011-2153-x. Epub
2011 Nov 29.

29. Sheiner E, Shoham-Vardi I, Weitzman D, Gohar J, Carmi R. Decisions regarding
pregnancy termination among Bedouin couples referred to third level ultrasound
30. https://www.health.gov.il/hozer/mr02_2018.pdf. (HEB)

31. Zlotogora J¹. Hum Genet. 2019 Oct;138(10):1117-1122. doi: 10.1007/s00439-019-02043-3. Epub 2019 Jun 26. Autosomal recessive diseases among the Israeli Arabs.